Aesthetic Medical International Holdings Group Ltd.

Good morning, ladies and gentlemen. Thank you for standing by, and welcome to Aesthetic Medical International third quarter 2022 earnings conference call. During today's presentation, all parties will be in listen-only mode. As a reminder, today's conference call is being recorded. On the call today from Aesthetic Medical International are Dr. Pengu Zhou, Chairman and Chief Executive Officer, Mr. Toby Wu, Chief Financial Officer, and Mr. Derek Shih, Investor Relations Associate Director. Dr. Joe will review the business operations and the company highlights, followed by Mr. Toby Wu, who will introduce the company's financial performance. They will all be available to answer your questions during the Q&A session that follows. Before we get started, I'd like to remind you that some of the information discussed will include forward-looking statements regarding future events and our future financial performance. These include statements about our future expectations financial projections, and our plans and prospects. Actual results may differ materially from those set forth in such statements. For discussion of these risks and uncertainties, you should review the company's filings with the SEC, which includes today's press release. You should not rely on our forward-looking statements as predictions of future events. All forward-looking statements that we make on this call are based on assumptions and beliefs as of today, and we undertake no obligation to update them except as required by applicable law. Our discussion today will include non-IFRS financial measures, including EBITDA, adjusted loss, and adjusted EBITDA. You should not consider EBITDA, adjusted EBITDA, or adjusted loss as a substitute for or superior to net income prepared in accordance with IFRS. Furthermore, because of non-IFRS, Measures are not prepared in accordance with IFRS. They're susceptible to varying calculations and may not be comparable to other similarly titled measures presented by other companies. You're encouraged to review the company's financial information in its entirety and not rely on a single financial measure. At this time, I would like to turn the call over to Dr. Peng Gujo, Chairman and CEO of Aesthetic Medical International. His opening remarks will be delivered in English by Investor Relations Associate Director, Mr. Derek Shi. Dr. Zhou, please go ahead.

In order to reduce the impact on people's daily life and business operations, the country has adjusted the prevention and control strategy from the original wide wind control in a certain area to now more accurately implement specific area of control and shorten the control period. Even so, the company is still affected by the wind control measures in the third quarter. Thank you everyone for joining the call today. The third quarter of 2022 was still clouded by the

the uncertainties arising from the resurgence of COVID-19 pandemic. To mitigate the impact on people's daily living and business operations, the country has adjusted its strategy of prevention and control measures from a broad coverage of a region to a more precise implementation of specific areas with shortened lockdown periods. Yet Shenzhen was placed under lockdown and three of the group's treatment centers were forced to close temporarily in September, which affected our customer traffic. As a result, revenue of this quarter slightly decreased by 0.3% year-over-year.